The safe administration of thrombolytic agents is a challenge for the treatment of acute
thrombosis. Lipid‐based nanoparticle drug delivery technologies present opportunities to …

Purpose To test the hypothesis that thrombus-specific tissue plasminogen activator (tPA)-
loaded nanocarriers enhance thrombolytic efficacy and attenuate hemorrhagic …

The goal of the present work was to design and test an acute-use nanoparticle-based
antithrombotic agent that exhibits sustained local inhibition of thrombin without requiring a …

Thrombolytic (clot-busting) therapies with plasminogen activators (PAs) are first-line
treatments against acute thrombosis and ischemic stroke. However, limitations such as …

Lipidic nanoparticles have undergone extensive research toward the exploration of their
diverse therapeutic applications. Although several liposomal formulations are in the clinic …

Several plasminogen activators (PAs) have been found effective in treating different
thromboembolic diseases. However, administration of conventional thrombolytic therapy is …

It remains a major challenge to develop a selective and effective fibrinolytic system for
thrombolysis with minimal undesirable side effects. Herein, we report a multifunctional …

The use of lipid-based nanoparticles for the delivery of biomacromolecules has attracted
considerable attention due to the current interest in protein-based therapeutics. Cubosomes …

Thrombosis or embolism is the leading cause of death and long-term adult disability
worldwide. To reduce the risk of thrombosis and hemorrhaging in patients, a facile and …

Various strategies are being developed to improve delivery and increase the biological half-
lives of pharmacological agents. To address these issues, drug delivery technologies rely on …